BUSINESS
    MSD Japan Embarking on 2-Step Spinoff for Women’s Health, Legacy Brands
    February 28, 2020
    After US Merck announced its spinoff plan earlier this month for women’s health, biosimilar, and legacy brand franchises, the New Jersey behemoth’s Japan unit is setting out to a two-step transition, envisaging the launch of…

    LATEST

    Takeda Snaps Up PvP Biologics, Gets Another Celiac Disease Drug
    February 28, 2020
    Takeda Pharmaceutical has exercised its option to acquire PvP Biologics as it took heart from PI proof-of-mechanism data from TAK-062, subject to their “build to buy” deal inked a few years back, the Japanese company said on February 26.Under thedeal…
    Japan Infectious Diseases Society Shares Latest Knowledge on Antivirals against COVID-19
    February 28, 2020
    The Japanese Association for Infectious Diseases compiled a paper on February 26 sharing its latest knowledge on the use of antivirals for the treatment of novel coronavirus disease (COVID-19).While noting that there is no drug approved that carries an indication…
    Gilead Launches PIII Studies for Remdesivir for COVID-19, Japan Included
    February 28, 2020
    Gilead Sciences said on February 26 that it is initiating two PIII clinical trials for its investigational antiviral remdesivir for the treatment of novel coronavirus disease (COVID-19), covering some 1,000 patients mainly across Asian countries.…

    INTERVIEW

    Improper Materials Apparently Decreased after Promotion Guidelines Introduced: Pharmacist
    By Takamitsu Sasai

    Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…

    Impact of Oligonucleotides

    Impact of Oligonucleotides - 3: Advances in Modified Oligo Technologies Pave Way for Innovative Drug Arrivals
    By Takashi Ebisawa

    Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…

    FY2020 Drug Pricing Reform

    Japan Panel Hammers Out FY2020 Drug Pricing Reform

    Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…

    Reimbursement Listing in 2018-2019

    Japan’s First Biosimilars of Avastin, Nesp, Forteo Receive Listing

    The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…

    TRENDS

    51 Drugs Listed in 2019 with Total Peak Sales Forecast of 370 Billion Yen, Many for Orphan Diseases

    A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…

    COMMENTARY

    Unison Capital Shows Rising Presence with Kyowa Deal, PE Fund Potential Catalyst for Industry Shakeup?
    By Reiji Anasako

    Indian generic maker Lupin is casting off Kyowa Pharmaceutical Industry, which it acquired in 2007. Forking over 57.4 billion yen…

    FY2018 Earnings Roundup

    Japanese Drug Makers Beefing Up China Biz amid Regulatory Tailwind
    By Reiji Anasako

    Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…

    My Viewpoint on CEA

    Ensuring Patient Access Was MHLW’s Top Priority for CEA Scheme: Policy Planning Director
    By Yoshinori Sagehashi

    Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…

    HTA Debates in 2018-2019

    Japan to Roll Out Cost-Effectiveness Assessment Scheme in April

    Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

    COLUMN

    A Peek into the Digital Pharmaceutical Industry
    By Philip Carrigan

    While the digital transformation may only be in its infancy in the pharmaceutical industry, the winds of change are here. It’s only a matter of time until customers and patients demand a higher level of service, experience, and connectivity from…

    NEWS CATEGORY

    REGULATORY

    BUSINESS

    ORGANIZATION

    ACADEMIA